GlassScriptPhysician profile
Lyn E Yakubov
NPI 1144222746
$2,446.01
in general payments reported to CMS, 2019-2025
21 companies · $958 in 2025
The $958 reported for 2025 was more than what 76% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $567 · 2020: $13.99 · 2021: $207 · 2022: $258 · 2023: $180 · 2024: $262 · 2025: $958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,399.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $983.57 | 2019-2025 | Unity, Clareon, Clareon Panoptix Pro |
| New World Medical,INC. | $171.90 | 2025 | Ahmed Glaucoma Valve, Kahook Dual Blade, Streamline |
| Johnson & Johnson Surgical Vision, INC. | $129.96 | 2024-2025 | Veritas Vision System, Tecnis Iol, Tecnis Simplicity |
| Mallinckrodt Hospital Products INC. | $116.90 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $115.13 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $99.98 | 2019 | |
| Carl Zeiss Meditec, INC. | $96.31 | 2019 | |
| Aerie Pharmaceuticals, INC. | $94.90 | 2019 | |
| Bausch & Lomb Americas INC. | $86.81 | 2025 | Xiidra, Miebo |
| Rayner Intraocular Lenses Limited | $79.56 | 2023-2025 | Omidria, Rayone Aspheric, Rayone Emv |
| Omeros Corporation | $56.62 | 2019 | |
| Horizon Therapeutics Plc | $54.62 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $52.60 | 2019 | |
| Optos, INC. | $50.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $47.41 | 2021-2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $46.70 | 2024 | Oxervate |
| Ocular Therapeutix, INC. | $46.57 | 2023 | Dextenza |
| Kala Pharmaceuticals, INC. | $43.34 | 2019-2021 | |
| Shire North American Group INC | $26.25 | 2019 | |
| Abbvie INC. | $24.06 | 2023 | Durysta |
| Oyster Point Pharma, INC. | $22.82 | 2023 | Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lyn Yakubov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.